Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?
about
Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injuryIs lipid signaling through cannabinoid 2 receptors part of a protective system?Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategiesQuantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) receptor antagonist.Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.The cannabinoid ligand LH-21 reduces anxiety and improves glucose handling in diet-induced obese pre-diabetic mice.The endocannabinoid system: potential for reducing cardiometabolic riskA new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity.Biodistribution and dosimetry in humans of two inverse agonists to image cannabinoid CB1 receptors using positron emission tomography.Psychopharmacology of the endocannabinoids: far beyond anandamide.Multiple functions of endocannabinoid signaling in the brain.Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysisCannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II.The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsEndocannabinoids rein in pain outside the brainAM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.Endocannabinoid signaling at the periphery: 50 years after THC.Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors.Activation of cannabinoid receptor type 1 (Cb1r) disrupts hepatic insulin receptor signaling via cyclic AMP-response element-binding protein H (Crebh)-mediated induction of Lipin1 gene.Natural prenylated resveratrol analogs arachidin-1 and -3 demonstrate improved glucuronidation profiles and have affinity for cannabinoid receptors.Modulating the endocannabinoid system in human health and disease--successes and failuresConformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat.Dissecting the role of CB1 receptors on chronic liver diseasesEndocannabinoids and cardiac contractile function: pathophysiological implications.The emerging role of the endocannabinoid system in cardiovascular disease.Latest advances in cannabinoid receptor agonists.Anti-obesity drugs: past, present and future.Cannabinoid 1 receptor in fatty liver.Cannabinoids: new promising agents in the treatment of neurological diseases.Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.Cannabinoid signaling in health and disease.Contribution of limbic norepinephrine to cannabinoid-induced aversion.Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors.Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.
P2860
Q24595633-C21B3231-5745-41BE-AD62-8C26C9022AF3Q24633122-9A516D8C-0CED-4E88-9CCB-009461383838Q28241318-CB12CC03-2874-416A-9D25-B7907755AA40Q33659650-97F3A9B3-8004-482C-BFDC-6055C0330BC4Q33773079-B668D916-94C1-4568-9619-FBBC04E091A3Q33822403-5AD032B5-F78B-461B-B08E-46DB03DFB08CQ33999727-3B80CEB4-5F21-464C-8DCA-7853BE29543CQ34011553-788254AA-6B5A-49A6-A563-B57A8457D310Q34044002-FDE6084E-1E60-466A-91E8-940E64514BE9Q34190754-9A2CC6AC-FFD5-47CC-88D8-2878D0DBE75DQ34270199-9593C2FE-C4C5-43B1-921D-67D589E08E41Q34500324-F419B836-58C0-4829-B8EB-83CB234D3894Q34718604-0485E186-73BA-4313-86E9-CD7594DC61FBQ34992139-563C8C0F-B1EC-45CA-B595-35DD2EAD3B51Q35048879-82973D6E-76FD-481D-A249-B4A1FFD59B19Q35193292-905451AF-15FC-4843-A30A-7CC76348273EQ35212014-B2AC29BB-A81E-4A5E-BC83-061C18619E7AQ35484505-32765025-F771-47ED-AF74-FB7C7439FB7EQ35572176-DF468DA4-8981-40BB-BBC5-C6CFE657C3FFQ35678770-7EB61A50-930D-4553-B060-55E32A5E99C8Q35785005-40BC079E-0BA9-4F83-8B69-D0C237F8C9A1Q36176472-B7B838F7-1D6E-440A-8488-998B73488124Q36225837-1868AF0F-D3CF-4051-9EBD-ACCF120D5450Q36368276-F94B2A76-24E1-4225-B35B-A742211E8D6DQ36717019-67917959-C2A5-4555-AA30-73D724709E87Q36933683-ADAC3EE7-10FA-4002-83C7-766C6232031BQ36956793-2A2E1105-F07E-4CCB-9289-B2E8EA7916A9Q37032490-9714F238-D6CC-47F9-8B72-9263770D749DQ37188637-E14A7B01-43F4-42AD-AF30-0EAC2410B037Q37401757-39AA828A-77FE-4961-9E0B-2EF482FAB2DFQ37439386-267E03AC-4757-420F-828D-9A133374E42EQ37638736-658BD393-8DA3-431B-887C-BAB256011B44Q38036925-AA84D4FA-51B1-4F1A-B42A-E62CDEEB3C8FQ38044956-16E89BC7-0BFF-4F6B-A536-39C671ED2CF3Q38269376-71AC55F1-791E-497F-901C-E41FFF49E5EBQ38973739-A77EAE93-DD9F-4280-8B25-63235825D41FQ39163671-A9DC0971-DB13-4475-BFAD-47D3EB95FC74Q40851777-EEA20DE5-91EF-43F2-8169-5CD9DC991CF4Q47357050-20D2B634-C41D-4EB4-865B-3D656C5070C7Q47797514-719DA0C5-630F-49DF-AC91-94BE84D30303
P2860
Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Should peripheral CB
@nl
Should peripheral CB(1) cannab ...... targeted for therapeutic gain?
@en
type
label
Should peripheral CB
@nl
Should peripheral CB(1) cannab ...... targeted for therapeutic gain?
@en
prefLabel
Should peripheral CB
@nl
Should peripheral CB(1) cannab ...... targeted for therapeutic gain?
@en
P2860
P50
P921
P1476
Should peripheral CB(1) cannab ...... targeted for therapeutic gain?
@en
P2093
George Kunos
Sándor Bátkai
P2860
P356
10.1016/J.TIPS.2008.10.001
P577
2008-11-29T00:00:00Z